Non-Hodgkins Lymphoma Treatment Market Top Companies Trends, Product Innovations, Technology and Revenue Status: Coherent Market Insights
Global Non-Hodgkin’s Lymphoma (NHL) Treatment Market
Non-Hodgkin’s Lymphoma (NHL) is a cancer that originates in the lymphatic system, which is the disease-fighting network spread throughout the body. In non-Hodgkin’s lymphoma, the tumors develop from lymphocytes (white blood cells). This type of cancer occurs due to abnormal functioning of B or T lymphocytes and leukocytes. Around 80% of the lymphomas arise in developing B cells and the remainder are said to arise in the developing T cells.
Request to download and view full ToC: https://www.coherentmarketinsights.com/ongoing-insight/toc/547
This cancer generally affects the bone marrow, lymph nodes, spleen, blood, and other organs that are part of lymphatic system. NHL patients are observed with symptoms, such as fever, weight loss, swelling of lymph nodes, anorexia, fatigue, and dyspnoea. Its treatment varies with fast or slow growth of the cells, and depends on whether it is spread across one area or different areas of the body. Various treatment options for NHL include immunotherapy, chemotherapy, stem cell transplantation, targeted therapy, monoclonal antibody therapy, and radiation therapy. Moreover, there are numerous products available for treating this condition, for example, Deltasone, Adcertis, Folotyn, Adriamycin, Prednicot, Leukeran, Velcade, Thioplex, and Decadron. Various small molecule-targeted therapies, such as idelalisib and ibrutinib, are the latest advancements in NHL treatment.
The future launch of new drugs is expected to support the growth of the global Non-Hodgkin’s Lymphoma treatment market. For instance, a new drug, called Axicabtagene ciloleucel, received a priority review status prior to its launch in 2017, to get commercialized as a second-line therapy for the NHL treatment.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/547
The Rituxan drug, which is used to treat NHL, has long been a front-line treatment regimen, though there has been an increasing resistance from rituximab. To overcome this resistance, several R&D practices took place in the market. For instance, Roche, Inc. is conducting the Phase III study of Gazyva/Gazyvaro in people with previously untreated large B-cell lymphoma. The extension of already marketed drugs, such as Velcade, Revlimid, and Adcetris, would be further contributing towards the global NHL treatment market growth. In 2016, the U.S. Government allocated around US$ 5.2 billion to the National Cancer Institute (NCI) for cancer research and training purposes.
Global Non-Hodgkin’s Lymphoma (NHL) Treatment Market Taxonomy
On the basis of type of NHL:
- B-cell lymphoma
- T-cell lymphoma
By end user:
Rising incidence of NHL to fuel the global market growth
Among regions, North America holds a major share in the global Non-Hodgkin’s Lymphoma treatment market, on account of the high incidence rate of blood cancers in the U.S. According to the Leukemia and Lymphoma Society, NHL is the seventh most common cancer in the U.S., and ranks fifth in the U.K. The National Cancer Institute estimated 72,580 new cancer cases, as well as around 20,150 deaths caused by NHL in 2016 in the U.S. Furthermore, the American Cancer Society estimated up to 20 cases of NHL, 6 cases of myeloma, and 13 cases of leukemia per 100,000 population in the U.S. in 2014. It is believed that NHL is much more common in men than in women.
To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/non-hodgkins-lymphoma-treatment-market-547
Strategies implemented by key players to drive the global market growth
The leading players participating in the global Non-Hodgkin’s Lymphoma treatment market are Novartis International AG, Pharmacyclics, Inc., Bayer AG, F. Hoffmann LA Roche, Amgen, Inc., Eli Lilly and Company, Nordic Nanovector A/S, and AbbVie, Inc. These players have been undertaking various collaborative strategies for clinical research in order to yield new drugs.
For instance, Novartis AG collaborated with Aduro Biotech in 2015 for the clinical trial of novel immuno-oncology product, called ADU-S100, to treat NHL. Furthermore, taking a step ahead, Roche launched a global network of immunotherapy centers, named Immunotherapy Centers of Research Excellence (imCORE) Network, in 2016. This network intends to develop potential therapies for NHL by developing drugs that would simulate one’s immune system to fight the disease.
Request Sample Copy of the Business Report: https://www.coherentmarketinsights.com/insight/request-sample/547About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire